Q-omics provides the consensus-scored CA3 profile across patient tissues and cancer cell-line models. CA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CA3 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CA3 protein abundance shows 23,423 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, LUAD, and HNSC as cancer lineages where CA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CA3 survival associations across molecular data types. CA3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CA3 RNA expression–survival associations across cancer types. High CA3 expression shows unfavorable associations in UCEC, LGG, LAML and COAD, but favorable associations in UCS and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CA3 RNA expression.
This table summarizes CA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CA3 shows lower tumor expression in LUAD, HNSC, LUSC, BLCA, BRCA and UCEC. The LUAD box plot shows higher CA3 RNA expression in normal versus tumor tissue (log2 FC = −2.976, t-test p < 0.001).
This table shows molecular features associated with CA3 in patient tissues and cancer cell lines. In patient samples, CA3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, CA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
